Bridging the Gap: Conference Workbook [International Conference on AIDS (12th: 1994: Geneva, Switzerland)]

Wednesday, July 1

POSTER SESSIONSTrackB32268-3

32268 Erythema of the proximal nailfold in HIV-infected patients: Frequency,
relation to hepatitis C virus and HIV-viral load
Peter H. Itin*; PH. Itin; S. Courvoisier; M. Battegay, Switzerland
32269 Acyclovir-resistant herpes zoster in 18 HIV-infected patients.
Results of treatment with foscarnet
Guillaume Breton*; C.E. Caumes Eric; FA.M. Fillet Anne-Marie;
L.C. Lecomte Claire; K.C. Katlama Christine; B.F Bricaire Francois, France
32270 Mucocutaneous problems in HIV-infected patients: A prospective cohort
study
Peter H. Itin*; Nathalie Schaub; S. Courvoisier; L. Sponagel; N. Gyr;
TH. Rufli; M. Battegay; PH. Itin, Switzerland
32271 Skin manifestations in patients under the combination theraphy (CT)
Marcio Serra, Brazil
32272 Skin manifestations as predictors of HIV-infection in Malawi
Dickman Zimba*; I. Hoffman; R. Royce; RN. Kazembe; R. Chakroborty;
C.C Daly; M.S. Cohen, Malawi
32273 Cutaneous disorders in HIV-infected children
Luminita-Monica Luminos*; M. Mardarescu; S. Petrea; I. Darasteanu,
Romania
32274 Mucocutaneous manifestations associated with HIV-infection in Romania
Elisabeta Otilia Benea*; V Benea, Romania
32275 Hypotestosteronism in the era of HAART
Dominique Anwar*; B. Hirschel; M. Sauvage; Swiss HIV Cohort Study
Group, Switzerland
32276 Proinflammatory cytokines and insulin Resistance in HIV-infection
Alberto Biglino, Italy
32277 Increased prevalence of diabetes mellitus in patients with HIV-infection
Alvan Fisher*; Molly Stenzel; A.E. Fisher, USA
32278 Cardiac involvement in Indian HIV population
Shashank Joshi*; A.K. Deshpande, India
32279 Complete HIV pol sequence in plasma and genital tract of women:
Genital reservoir and differential drug resistance
Guowei Fang*; H. Burger; K. Anastos; C. Chappey; D. Mayers; W Meyer;
B. Weiser, USA
32280 Frequency of transmission of drug-resistant variants in individuals with
primary HIV-1 infection
Sabine Yerly*; G. Schockmel; J.P Bru; B. Hirchel; L. Perrin, Switzerland
32281 Virological response in patients switching from AZT/3TC
or AZT/ddC to other double NRTI combinations
Veronica Miller*; Axel Moiler; A. Phillips; B. Morgenstern;
M. Kortenbusch; K. Hertogs; T. Lutz; S. Staszewski, Germany
32282 Detection of genotypic drug resistance to antiviral nucleoside inhibitors
in short-time pretreated and drug-naive HIV-1 infected patients as
predictor of treatment failure in high acting antiretroviral therapy
(HAART)
Anja Masuhr*; K. Arasteh; V. Simon; C. Mocklinghoff; A. Moll, Germany
32283 Correlation of phenotypic resistance and clinical efficacy of abacavir
in a phase III pediatric study
Susan C. Danehower*; C.D. Mitchell; C.A. Gilbert; A. Keller; M.L. Smiley;

S. V Hetherington; E.R. Lanier, USA

32284 Evidence for independent development of RT Inhibitor (RTI) resistance
patterns in cerebrospinal fluid (CSF) compartment
Philip Cunningham*; D. Smith; C. Satchell; D.A. Cooper; B.J. Brew, Australia
32285 Genotypic and phenotypic resistance to stavudine (d4T) after long-term
monotherapy
Africa Molguin*; U. Dietrich; A. Immelmann; V Soriano, Spain
32286 Virologic findings in patients with paradoxical responses to highly
active antiretroviral therapy (HAART)
Jeffrey Fessel*;J.F Krowka; M.S. Ascher; H. W Sheppard; B. Cuevas;
S. Kwok; C Christopherson, USA
32287 HIV genotypic predictors of antiviral response to saquinavir (SQV)/
Ritonavir (RTV) therapy in patients who have failed prior protease
inhibitors (Pl's): A clinical cohort study
Andrew Zolopa*; R. Shafer; A. Warford; J. Montoya; D. Katzenstein;
T Merigan, USA
32288 Transmission of protease inhibitor resistant HIV-1 to a recently infected
antiretroviral-naive man:The UCSF-options primary HIV project
Frederick Hecht*;J.O. Kahn; B. Dillon; M. Chesney; R.M. Grant, USA
32289 Phenotypic HIV resistance in vitro correlates with viral load response
to abacavir (1592, ABC) in vivo
E.R. Lanier*; M.L. Smiley; M.H. St Clair; G. Pearce; W Spreen; A. Cutrell;
S.W. Lafon, USA
32290 Antiretroviral drug resistance testing to support the clinical care
of patients with HIV/AIDS
Clive Loveday*; H. Devereux; L. Huckett; M. Johnson, UK
32291 Viral load and CD4+ outcome following genotypic antiretroviral
resistance testing (GART) in primary care settings in Atlanta, Georgia
Melanie Thompson*; L. Anisman; R. Hudson; R. Kauffman; M. Patino;
M. Tanner; R. Dudley, USA
32292 Genotypic Analysis for Resistance Testing (GART) as a clinical tool:
A retrospective analysis
James A. Newton*; A.S. Pemberton; W.W Emmons; D.L. Mayers, USA
32293 Viral resistance and viral load response to abacavir (ABC, 1592)
in an AIDS Dementia Complex Trial (CNAB 3001)
Randall Lanier*; Justin McArthur; J.H. Atkinson; R. Price; D. Clifford;
D. Simpson; G. Torres; G. Sturge, USA
32294 Prexistent mutations of the HIV protease gene were associated with
therapeutic failures in patients on a saquinavir/ritonavir therapy
Philip Cunningham*; G.R. Kaufmann; D. Sayer; D. Smith; M. French;
D.A. Cooper, Australia
32295 Long term viral suppression using quadruple drug combination
therapy in treatment experienced HIV/AIDS patients, following initial
proteasefailure
Clayton Barbour, II, USA
32296 Patients harbouring both the multinucleoside analogue resistance
mutation Q151M and the AZT resistance mutation T215Y/F carry these
two mutations on different HIV-1 quasispecies
Anne-Mieke Van Damme*; K. Van Laethem; V. de Vroey; J. Desmyter;
E. de Clercq; J.-C. Schmit; T Harrer; L. Ruiz; B. Clotet; S. Sprecher; P
Hermans, Belgium

144

12th World AIDS Conference Geneva